Skip to content
Screener

Monte Rosa Therapeutics, Inc. GLUE Q4 2025 Annual earnings

Reported March 17, 2026 · Before market open

Revenue$2.8MMiss by $12.8M
EPS-$0.54Miss by $0.19
Revenue estimate$15.6M
EPS estimate-$0.35

Next report

Nov 5, 2026 (in a month)
Revenue estimate$31.5M
EPS estimate-$0.24

Financials

Q4 2025

Income statement

See full
Revenue$2.8M-95.4%
Operating income-$49.7M—
Net income-$46.1M—
EPS (diluted)-$0.55—

Balance sheet

See full
Cash & equivalents$129.9M-42.1%
Total debt$39.2M-8.3%
Total equity$233.1M+4.5%
Total assets$448.7M+2.3%

Cash flow

See full
Operating cash flow-$43.0M-133%
CapEx$767.0K+319%
Free cash flow-$43.8M-134%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.02B+139%
Enterprise value$930.35M+280%
P/S8.3×+2.6×

Profitability

See full
Operating margin-43.8%—
Net margin-31.2%—
FCF margin-22.2%-72.5pp

Returns & leverage

See full
Return on equity-16.9%—
Debt / equity0.2×0.0×
Current ratio6.1×+3.7×

FAQ

When did Monte Rosa Therapeutics, Inc. report Q4 2025 earnings?
Monte Rosa Therapeutics, Inc. (GLUE) reported Q4 2025 earnings on March 17, 2026 before market open.
What were Monte Rosa Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Monte Rosa Therapeutics, Inc. reported revenue of $2.8M and eps of $-0.54 for Q4 2025.
Did Monte Rosa Therapeutics, Inc. beat estimates in Q4 2025?
Revenue missed the consensus estimate of $15.6M by $12.8M. EPS missed the consensus estimate of $-0.35 by $0.19.
How did Monte Rosa Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 95.4% from $60.6M a year earlier.
Where can I find Monte Rosa Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-109353) and the 10-K periodic report (0001193125-26-109360) directly on SEC EDGAR. The filing index links above go to sec.gov.